Stryker 3Q 2026: Revenue $6.52B, Net income $753M, EPS $1.96— 10-Q Summary
Stryker reported Q3 2026 revenue of $6.52B, up 7.6% YoY, but net income fell 12.3% to $753M and EPS declined 11.7% to $1.96. Growth was driven by higher unit volumes in MedSurg, Neurotechnology, and select Orthopaedics businesses. Management anticipates faster growth in lower-margin segments but notes supply and cybersecurity risks.
How this was made
The 30-second read
Why it matters
Revenue increased on higher unit volumes across MedSurg, Neurotechnology, and parts of Orthopaedics, while net income and diluted EPS declined, indicating profitability pressure. The filing also notes supply constraints and a cybersecurity disruption as operational risks.
Market read
For SYK traders, the key decision inputs are the reported revenue growth versus profit/EPS decline and the mention of operational risks that could affect near-term execution.
What to watch
The summary flags supply constraints and cybersecurity disruption as operational risks, but provides no quantified impact; traders may need to wait for management commentary in the full filing for margin drivers and risk severity.
Background
The piece is a brief summary of Stryker’s 3Q 2026 Form 10-Q filed Oct. 30, 2026.
Ticker impact
Stryker’s 3Q 2026 10-Q reports net sales $6.52B (+7.6% YoY), but net income fell 12.3% to $753M and diluted EPS dropped 11.7% to $1.96.
Likely mixed-to-negative near term as investors weigh revenue growth against falling net income and EPS, plus operational risks (supply constraints, cybersecurity disruption).
The article provides the company’s own quarterly figures and highlights operational risks, but it does not include guidance numbers or consensus comparisons that would sharpen directionality.
Market effects
Signals ongoing demand resilience in med-tech (unit-volume growth) but also margin and operational friction that can influence sentiment across medical devices.
U.S. sales growth outpaced international in the quarter, which may matter for regional revenue expectations.
International growth benefited from currency, suggesting FX can be a swing factor for reported growth in global med-tech peers.
Counterpoint
EPS/net income declines could be temporary (timing of costs, mix, or one-off disruptions), while unit-volume growth suggests underlying demand remains intact.
Key entities
- companyStryker
Med-tech company reporting 3Q 2026 results in its 10-Q, including revenue, net income, and EPS changes.
- business segmentOrtho Tech and Instruments
Orthopaedic instruments and enabling technologies reorganized into new reporting groupings.
